Precision Biosciences (DTIL) Other Non-Current Liabilities (2020 - 2026)

Precision Biosciences (DTIL) has 7 years of Other Non-Current Liabilities data on file, last reported at $22.8 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $22.8 million, up 11474.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.8 million (up 11474.62% YoY), and the FY2025 annual result was $15.7 million, up 56.95% from the prior year.
• Other Non-Current Liabilities rose to $22.8 million in Q1 2026 per DTIL's latest filing, from $15.7 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $22.8 million in Q1 2026 and troughed at $188000.0 in Q3 2024.
• A 5-year average of $8.0 million and a median of $10.0 million in 2022 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities sank 99.11% in 2025, then soared 11474.62% in 2026.
• A 5-year view of Other Non-Current Liabilities shows it stood at $201000.0 in 2022, then jumped by 4875.12% to $10.0 million in 2023, then changed by 0.0% to $10.0 million in 2024, then surged by 56.95% to $15.7 million in 2025, then jumped by 45.28% to $22.8 million in 2026.
• Business Quant data shows DTIL's Other Non-Current Liabilities at $22.8 million in Q1 2026, $15.7 million in Q4 2025, and $4.0 million in Q3 2025.